Colipral

Currently, there is limited information available regarding the molecular or physiological mechanism of action for Colipral® (Escherichia Coli 5C, ECP24®), based on the lack of findings from PubMed and the status of clinical trials listed as "NOT_YET_RECRUITING." These trials aim to explore the potential uses of Colipral® in various contexts, such as preventing recurrent cystitis in menopausal women, evaluating effects on gut microbiota in ulcerative colitis, and alleviating post-colonoscopy gastrointestinal symptoms.

Since these trials have not yet recruited participants, no results or conclusions about the specific mechanisms of Colipral® are available. Further research is needed to establish how this probiotic strain interacts at a molecular or physiological level in each of these conditions.

Disclaimer: This information is for educational purposes only and should not be taken as medical advice. Always consult a healthcare professional for medical concerns.

Colipral is being investigated for several potential clinical applications, based on preliminary evidence from clinical trials. Here's a summary of its evaluated uses:

1. Prevention of Recurrent Cystitis in Menopausal Women: The trial titled "Colipral® (Probiotic Strain Escherichia Coli 5C (ECP24®)) for Prevention of Recurrent Cystitis in Menopausal Women" aims to assess the effectiveness of Colipral in preventing recurrent bladder infections, particularly in menopausal women. As of now, the research has not yet commenced (status: NOT_YET_RECRUITING), so no findings are available at this time.

2. Ulcerative Colitis During Remission: Another ongoing investigation, "Evaluation of the Effects of Colipral on Microbiota Gut Composition in Patients Presenting With Ulcerative Colitis During Remission Phase and Functional Disorders," plans to explore how Colipral impacts gut microbiota composition in patients with ulcerative colitis. This study is also in the preliminary stages (status: NOT_YET_RECRUITING), and results have not been published.

3. Post-Colonoscopy Gastrointestinal Symptoms: The study "Effect of Escherichia Coli 5C (Colipral®) on Post-Colonoscopy Gastrointestinal Symptoms" intends to evaluate Colipral's effect on gastrointestinal symptoms following a colonoscopy. Like the others, this trial is still in the planning phase (status: NOT_YET_RECRUITING), leaving the outcomes to be determined.

At this point, clinical applications of Colipral are largely hypothetical, pending results from these pending trials. Further evidence is required to substantiate its efficacy and safety for these conditions.

Disclaimer: This is not personalized medical advice. Consult with a healthcare provider for advice tailored to individual health needs.

There is currently limited information available on the safety profile of Colipral, as there are no completed clinical trials or studies providing data on its side effects, contraindications, or drug interactions. The existing trials are not yet recruiting, and therefore, no safety data has been published.

Given the lack of evidence from completed studies or trials:

• Known Side Effects: Not established due to the absence of published studies or completed trials.

• Contraindications: No information is available to define specific contraindications for Colipral.

• Drug Interactions: There are no documented interactions with other medications, as no studies have been published.

• Populations to Avoid: Without clinical evidence, it is not clear which populations should avoid Colipral. However, caution is generally advised for populations that are vulnerable, such as pregnant or breastfeeding women, until more data becomes available.

In summary, the safety profile of Colipral remains undefined due to the lack of evidence. As the clinical trials progress and more data becomes available, a clearer understanding of its safety will likely emerge.

Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult healthcare professionals for individual treatment and diagnosis.

As of now, there are no published research papers or completed clinical trials available on "Colipral" according to PubMed, which suggests that evidence regarding this therapy is still developing.

Currently, three clinical trials are registered:

1. Prevention of Recurrent Cystitis: This trial is focused on menopausal women and aims to evaluate the effectiveness of Colipral, a probiotic strain known as Escherichia Coli 5C (ECP24®), in preventing recurrent bladder infections. The trial is not yet recruiting, and specific details such as sample size or study duration have not been disclosed.

2. Gut Microbiota Composition in Ulcerative Colitis: This study will assess how Colipral affects gut microbiota in patients with ulcerative colitis who are in remission and experiencing functional disorders. Like the first trial, it is not yet recruiting, with no additional design details available.

3. Post-Colonoscopy Gastrointestinal Symptoms: This trial aims to determine the effects of Escherichia Coli 5C (Colipral®) on gastrointestinal symptoms following a colonoscopy. Recruitment for this study has not started, and no further information about the sample size or methodology is available.

Each of these studies is still in the early stages with no recruitment started, indicating that conclusions around the efficacy and safety of Colipral cannot yet be drawn.

Disclaimer: This content is informational and not a substitute for professional medical advice. Always consult your healthcare provider for guidance tailored to your health circumstances.

Currently, there are no published studies or clinical protocols available for the dosing or administration of Colipral as no clinical trials have reported results. The identified studies are all in the planning stage and have not yet commenced. As a result, specific dosing guidelines and administration protocols cannot be provided at this time.

Disclaimer: This information is for educational purposes only and not intended as medical advice. Always consult a healthcare professional for medical guidance tailored to your health situation.

Outcomes Summary for Colipral

As of now, there is no published literature available on PubMed regarding the outcomes of Colipral. Additionally, three clinical trials (NCT07676604, NCT07751081, NCT07519616) are registered but have not yet begun recruiting participants. These trials aim to investigate various potential outcomes of Colipral:

1. Prevention of Recurrent Cystitis in Menopausal Women: This trial will explore whether Colipral can help prevent recurrent cystitis, which is a common issue among menopausal women. No outcomes have been reported yet.

2. Effects on Gut Microbiota in Ulcerative Colitis: This study aims to evaluate how Colipral affects gut microbiota composition in patients with ulcerative colitis in remission. Outcomes regarding microbiota changes and functional gastrointestinal symptoms will be observed once the trial is conducted.

3. Post-Colonoscopy Gastrointestinal Symptoms: This trial seeks to determine the effect of Colipral on gastrointestinal symptoms following a colonoscopy. Specific measurable outcomes will likely include symptom severity and duration, though no results are yet available.

Since these studies have not started recruiting, there are no data or measurable outcomes reported for Colipral at this time. The evidence in this area remains currently nonexistent, and updates will depend on the initiation and completion of these trials.

Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. Always consult a healthcare provider for medical concerns.